|
Market Closed -
Nasdaq
00:00:00 25/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 23.88 USD | -1.57% |
|
+0.72% | +55.98% |
| 09-01 | Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating | MT |
| 08-06 | Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.8B | - | - | - | ||
| 74.18B | |||||
| 59.55B | |||||
| 25.84B | - | ||||
| 24.73B | - | ||||
| 20.87B |
- Stock Market
- Stocks
- XNCR Stock
- Charts Xencor, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
